ARTICLES BY MARTIN LUSH
-
After COVID-19: Time To Rethink, Redesign, & Reprioritize Everything6/8/2020
As we navigate the uncertainty ahead, two things are certain: 1) We will get through this, and (2) the post COVID-19 environment will be very different — but will it be better?
-
Rebels Vs. Clones: Constructive Dissent In The Pharma Industry12/20/2019
The pharma industry is in the middle of an identity crisis, but not in the way you may think. Rather than a period of uncertainty and confusion typically brought on by a change in role or expectations, this crisis is far more insidious. It’s brought on by a mind-set in which industry leaders believe they know exactly what the industry should be doing.
-
15 Bold Predictions About Healthcare's Future — And What Bio/Pharma Must Do To Prosper In It3/30/2018
Ever participated on one of those benchmarking exercises? You know what I mean: a (usually) fresh-faced consultant asks lots of questions and fills in a spreadsheet comparing what you do with your competitors. Well, beware.
-
Responding To Regulatory Inspection Observations: Do's and Don'ts6/26/2017
Although good auditors base conclusions on facts, emotions will play an important role in how they perceive your company, your leadership, and your quality culture. This is not a precise process, and cultural differences can often sabotage good intent.
-
What Would Steve Jobs Tell The Pharma/Biotech Industry?5/15/2017
Whether you’re a fan of Steve Jobs and his products or not, two things are undeniable: He was very successful and very different. In this article, we encourage our industry to radically change — not by reinventing the wheel, but by copying the success of others.
-
Brexit, Trump, What Next? 6 Rules To Succeed In An Era Of 'Brutal Disruption'2/8/2017
Heard the latest? Elvis is alive and kicking and planning a comeback. Only kidding … but who knows? After the events of 2016, anything is possible.